MTIP takes majority stake in Verifarma
Context
MTIP has completed a majority strategic investment in Verifarma, a Spain,headquartered software provider. The transaction is designed to propel the next phase of the company's growth, with a specific focus on international scaling and technological advancement. All four co,founders, including the CEO, CFO, COO, and Chief AI Officer, will continue to lead the business post,investment, ensuring management continuity and the preservation of long,term customer relationships. The strategic rationale for the partnership involves significant investment in the core track,and,trace technology platform and the expansion of AI,driven quality management features. Furthermore, the capital will be used to strengthen the group's go,to,market infrastructure in Europe and to further penetrate the Latin American market. This investment aligns with the growing global demand for rigorous pharmaceutical traceability and regulatory compliance, positioning the organization as a leading international player in the healthtech space. MTIP intends to leverage its extensive experience in scaling healthcare technology companies to support the entity's continued internationalization and platform development.
Verifarma, which reported an EBITDA margin of [members only] in 2025, is valued in this transaction at an EV/EBITDA multiple of [members only].
-> Deep-dive in TMT (Tech, Media, Telecom) market trends
Target
Verifarma is a high, growth SaaS provider specializing in integrated serialization, traceability, and regulatory compliance solutions tailored for the pharmaceutical industry. The organization provides an end,to,end software platform that supports pharmaceutical manufacturers, wholesalers, and distributors in navigating complex global traceability requirements. Its technology spans the entire supply chain, ensuring the safety and authenticity of medicines by tracking products from production to the end consumer. Established in 2007, the entity has developed a leading position in the Latin American market and is rapidly expanding its footprint across Europe. With a mission focused on supply chain integrity, the company serves a diverse global client base, leveraging AI,driven capabilities to enhance quality management and track,and,trace efficiency for more than 2,000 companies.
Ent. Value
[members only]
Equity Value
[members only]
Multiples
EV / Revenue
[members only]
EV / EBITDA
[members only]
EV / EBIT
[members only]
Historical Financials (EUR)
Similar deals in Software
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 04/2026 | ATHOS CONSORTIUM / A.P. MOLLER HOLDING | DOCTOLIB | FRANCE | Healthcare |
| 04/2026 | RELX | DOCTRINE | FRANCE | Industry-Specific Software |
| 03/2026 | TOTAL SPECIFIC SOLUTIONS (TSS) | CYBERJET | FRANCE | Defense & Aerospace |
| 03/2026 | ASMODEE GROUP | ATM GAMING | FRANCE | Gaming & Consumer Apps |
| 03/2026 | MANAGEMENT & PRIVATE INVESTORS | MASA GROUP | FRANCE | Defense & Aerospace |
| 03/2026 | MANAGEMENT & PRIVATE INVESTORS | RIVALIS-HENRRI | FRANCE | ERP, HR & Finance |
| 03/2026 | NORVESTOR | ZALARIS | NORWAY | ERP, HR & Finance |
| 03/2026 | MAIN CAPITAL PARTNERS | GINGCO SYSTEMS | GERMANY | Collaboration & Productivity |
| 03/2026 | INSIGHT PARTNERS | WONDERFUL | NETHERLANDS | Data, Analytics & AI |
| 03/2026 | AXCEL | GEOMATIKK | NORWAY | Industry-Specific Software |
REFERENCES
Revenue range: REV €5–25M
EBITDA range: €0–5M
Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of Verifarma by MTIP are reserved for mynth community members. Register for free to unlock full data.
Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.
Target: verifarma
FAQ
What transaction does this page cover?
What were Verifarma’s revenue and EBITDA at the time of the deal?
What sources support the information on this transaction?
What is mynth?